The TS-8 14 project was restarted on 1985, and was listed as "National Eighth Five-Year Scientific Research Public Relations Project" by the State Science and Technology Commission.
1994, Shenhong Quyu Sanjie Capsule was successfully developed on the basis of Shenhong Zhuishun Powder by using modern biological gene technology, and officially entered clinical trials.
On March 4, 2002, National Medical Products Administration approved it as: National Medicine Zhunzi B20020060, becoming the first national medicine Zhunzi biological gene anticancer drug in China;
On March 8, 2002, at the 27th World Report on Scientific and Technological Achievements held in Beijing, Shenhong Quyu Sanjie Capsule won the highest award in the conference-the Innovation Invention Award, and the main researcher Professor Wang Daishu won the "Special Contribution Award".
On March 18, 2003, at the press conference, the scientific research unit and honorary manufacturer of "Shenhong Capsule", together with the 27th report on world scientific and technological achievements, announced that Shenhong Quyu Sanjie Capsule was officially and fully produced and listed for the benefit of all beings.
On June 5438+1October 65438+July, 2005, at the launching ceremony of "National Cancer Rehabilitation Promotion Project" held in the Great Hall of the People in Beijing, Shenhong Quyu Sanjie Capsule, the only genetic anticancer drug in China, was unanimously recommended as the most ideal drug for the treatment of tumors by more than 300 cancer treatment authorities attending the meeting, and was listed as the only designated drug in the "National Cancer Rehabilitation Promotion Project".